Cash from Operations (Annual) Chart

View Cash from Operations (Annual) for SVRA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Annual) Chart
Start Trial

Historical Cash from Operations (Annual) Data

View and export this data back to 2000. Start Trial.
Date Value
December 31, 2025 -101.04M
December 31, 2024 -89.09M
December 31, 2023 -51.06M
December 31, 2022 -34.55M
December 31, 2021 -40.08M
December 31, 2020 -39.84M
December 31, 2019 -45.12M
December 31, 2018 -39.28M
December 31, 2017 -28.23M
December 31, 2016 -8.37M
December 31, 2015 -32.95M
December 31, 2014 -24.64M
December 31, 2013 -17.79M
Date Value
December 31, 2012 -13.92M
December 31, 2011 -13.47M
December 31, 2010 -8.341M
December 31, 2009 -12.62M
December 31, 2008 -23.79M
December 31, 2007 -19.64M
December 31, 2006 -15.77M
December 31, 2005 -11.65M
December 31, 2004 -5.175M
December 31, 2003 -2.247M
December 31, 2002 -1.102M
December 31, 2001 -1.711M
December 31, 2000 -2.148M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
Gilead Sciences, Inc. 10.02B
Insmed, Inc. -935.01M
United Therapeutics Corp. 1.561B
Vertex Pharmaceuticals, Inc. 3.631B
SELLAS Life Sciences Group, Inc. -28.39M